Our CEO Tamer Mohamed will be in Japan with our Manager of Industry Alliances, Jacek Mis, for BioJapan and Regenerative Medicine Japan 2019. This is Asia's premier partnering event for the global biotechnology industry and we are excited to be attending for the third year.
Tamer will be speaking about 3D bioprinting for regenerative medicine on the open seminar stage and will be participating as a Canadian Investment Champion Speaker for Global Affairs Canada's Foreign Direct Investment initiative to outline Canada's capabilities and investment opportunities in the life sciences biotechnology sector.
Canada Life Sciences Seminar at BioJapan
When: October 9, 12:00-13:00
Where: Room F202
When: October 10, 13:30-13:45
Where: Seminar Stage (Open Stage)
Abstract: Aspect Biosystems is a Canadian biotechnology company operating at the leading edge of 3D printing and regenerative medicine. Our proprietary microfluidic 3D bioprinting platform is enabling advances in biology, disease research, drug discovery, and regenerative medicine. Aspects current clinical pipeline of therapeutic tissues has two main areas of focus: orthopaedic implants and cellularized implants for metabolic diseases. Our lead orthopaedic indication is a personalized 3D printed meniscus tissue for treatment of patients with severe meniscal tears. Our second lead indication in preclinical development is an implantable 3D printed allogeneic tissue patch for treatment of Type 1 Diabetes. In addition to our internal therapeutic tissue programs, we strategically partner with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate drug discovery and development, and enable the creation of cutting edge tissue therapies of the future.
Contact us to arrange a meeting with Tamer or Jacek while they are in Japan.